Publication
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerMalignant Neoplasmcivic_curation1.00
- drugCapecitabinecivic_curation1.00
- drugFluorouracilcivic_curation1.00
- drugTegafurcivic_curation1.00
- geneDPYDcivic_curation1.00
- variantDPYD DPYD*13 HOMOZYGOSITYcivic_curation1.00
- variantDPYD DPYD*2A HOMOZYGOSITYcivic_curation1.00
- variantDPYD RS67376798 HOMOZYGOSITYcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23988873
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| DPYD DPYD*13 HOMOZYGOSITY1 | ||||||||
| Capecitabine + Fluorouracil + TegafurSubstitutes | Malignant NeoplasmALIAS | Predictive | A | Supports Adverse Response | 5 | accepted | EID1801The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67… (full text at CIViC) PMID 23988873 · Caudle et al., 2013 · Open in CIViC | civic |
| DPYD DPYD*2A HOMOZYGOSITY1 | ||||||||
| Capecitabine + Fluorouracil + TegafurSubstitutes | Malignant NeoplasmALIAS | Predictive | A | Supports Adverse Response | 5 | accepted | EID1800The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67… (full text at CIViC) PMID 23988873 · Caudle et al., 2013 · Open in CIViC | civic |
| DPYD RS67376798 HOMOZYGOSITY1 | ||||||||
| Capecitabine + Fluorouracil + TegafurSubstitutes | Malignant NeoplasmALIAS | Predictive | A | Supports Adverse Response | 5 | accepted | EID1803The Clinical Pharmacogenomics Implementation Consortium Guidelines for DPYD genotype and 5-FU dosing does not recommend the use of 5-FU or capecitabine in patients with homozygous DPYD*2A, *13 or rs67… (full text at CIViC) PMID 23988873 · Caudle et al., 2013 · Open in CIViC | civic |